Trial NCT03251924

View at ClinicalTrials.gov 
Org. Study IDs: CA021-002
Secondary IDs: 2017-000238-73

Last trial update was posted on 2023-02-28

MeSH Interventions

Antibodies Antibodies, Blocking Immunoglobulins Ipilimumab Nivolumab

MeSH Conditions

Neoplasms

Other Conditions

Cancer Malignancy Neoplasm Tumors

Stopping Reasons

Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226.

Limitations And Caveats

Study CA021002 was terminated because the Sponsor discontinued further development of BMS-986226. The decision for the study closure was not related to any safety concerns associated with BMS-986226.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID